Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05476926
Registration number
NCT05476926
Ethics application status
Date submitted
25/07/2022
Date registered
27/07/2022
Date last updated
4/06/2024
Titles & IDs
Public title
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Query!
Scientific title
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)
Query!
Secondary ID [1]
0
0
MR41927
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
VOYAGER
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neovascular Age-related Macular Degeneration
0
0
Query!
Diabetic Macular Edema
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Faricimab
Combination Product - Port Delivery System with Ranibizumab
Faricimab for nAMD -
Faricimab for DME -
Port Delivery System with Ranibizumab for nAMD -
Treatment: Drugs: Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Combination Product: Port Delivery System with Ranibizumab
The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Combination Product
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product
Query!
Assessment method [1]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [1]
0
0
Baseline and 1 year
Query!
Secondary outcome [1]
0
0
Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product
Query!
Assessment method [1]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [1]
0
0
Baseline, 3 and 6 months, and 2, 3, 4, and 5 years
Query!
Secondary outcome [2]
0
0
Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Retinal Indication and Product
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [3]
0
0
Number of Treatments per Year, per Approved Retinal Indication and Product
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
1, 2, 3, 4, and 5 years
Query!
Secondary outcome [4]
0
0
Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
From Baseline until end of study (up to 5 years)
Query!
Secondary outcome [5]
0
0
Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
At 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [6]
0
0
Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time, per Approved Retinal Indication and Product
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
At 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [7]
0
0
Total Number of Visits per Year, per Approved Retinal Indication and Product
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
1, 2, 3, 4, and 5 years
Query!
Secondary outcome [8]
0
0
Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
1, 2, 3, 4, and 5 years
Query!
Secondary outcome [9]
0
0
Time Interval Between Treatments per Year, per Approved Retinal Indication and Product
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
1, 2, 3, 4, and 5 years
Query!
Secondary outcome [10]
0
0
Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per Approved Retinal Indication and Product
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
From Baseline until end of study (up to 5 years)
Query!
Secondary outcome [11]
0
0
Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product
Query!
Assessment method [11]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [11]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [12]
0
0
Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and Product
Query!
Assessment method [12]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [12]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [13]
0
0
Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication and Product
Query!
Assessment method [13]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [13]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [14]
0
0
Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and Product
Query!
Assessment method [14]
0
0
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Query!
Timepoint [14]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [15]
0
0
Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Baseline, 3 and 6 months, and 1, 2, 3, 4, and 5 years
Query!
Secondary outcome [16]
0
0
Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product
Query!
Assessment method [16]
0
0
Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.
Query!
Timepoint [16]
0
0
From Baseline until end of study (up to 5 years)
Query!
Secondary outcome [17]
0
0
Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product
Query!
Assessment method [17]
0
0
Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.
Query!
Timepoint [17]
0
0
From Baseline until end of study (up to 5 years)
Query!
Eligibility
Key inclusion criteria
1. Have provided informed consent, as required per local regulations 2.a) Adult patient, as
defined by local regulations and local product label, who is newly initiating treatment (or
initiated treatment in the previous visit) with a specified approved Roche ophthalmology
product in retinal indication of interest for this study in at least one eye, according to
the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as
defined by local regulations and local product label, who is continuing treatment with any
specified approved Roche ophthalmology product in retinal indication of interest for this
study in at least one eye after initiating that treatment in a Roche interventional trial.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Concomitant participation of the patient in an investigational ophthalmology clinical
trial that includes receipt of any investigational drug or procedure within the last 28
days prior to enrollment (this restriction does not apply to patients who are rolling over
from Roche interventional studies and continuing treatment with any specified approved
Roche ophthalmology product in retinal indication of interest for this study)
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/11/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2027
Query!
Actual
Query!
Sample size
Target
5000
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Retina and Macula Specialists - Hurstville
Query!
Recruitment hospital [2]
0
0
Sunshine Coast University Hospital - Geebung
Query!
Recruitment hospital [3]
0
0
Cabrini Hospital Malvern - Malvern
Query!
Recruitment hospital [4]
0
0
Lions Outback Vision Service in Broome - Broome
Query!
Recruitment postcode(s) [1]
0
0
2220 - Hurstville
Query!
Recruitment postcode(s) [2]
0
0
4034 - Geebung
Query!
Recruitment postcode(s) [3]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [4]
0
0
6725 - Broome
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
South Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Utah
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Sofia
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Varna
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Chile
Query!
State/province [20]
0
0
Las Condes
Query!
Country [21]
0
0
Chile
Query!
State/province [21]
0
0
Vitacura
Query!
Country [22]
0
0
Croatia
Query!
State/province [22]
0
0
Osijek
Query!
Country [23]
0
0
Croatia
Query!
State/province [23]
0
0
Zagreb
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Praha 6
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bordeaux Floirac
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Bordeaux
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Creteil cedex
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Dijon Cedex
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Ecully
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
La Rochelle cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Le Chesnay Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Lyon
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Marseille
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Montargis
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Montauban
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Montpellier
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Nantes cedex 1
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Nantes
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Nice
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Paris
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Saint Etienne
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
St Cyr Sur Loire
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
St Herblain
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Toulouse
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Berlin
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Chemnitz
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Dresden
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Frankfurt
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Greifswald
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hannover
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Heidelberg
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Leipzig
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Ludwigshafen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Magdeburg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Mannheim
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Rostock
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Haifa
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Jerusalem
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Calabria
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Campania
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Friuli-Venezia Giulia
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Lazio
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Liguria
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Lombardia
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Piemonte
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Sardegna
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Sicilia
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Aichi
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Chiba
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Chuo-shi
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Fukuoka
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Gifu
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Hiroshima
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Hokkaido
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Hyogo
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Ibaraki
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Kagawa
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Kanagawa
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Meguro-ku
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Mie
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Nagano
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Nagasaki
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Osaka-shi
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Osaka
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Saitama
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Shiga
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Suita
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Takatsuki-shi
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Tokushima
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Tokyo
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Yamaguchi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Yoshida-gun
Query!
Country [94]
0
0
Puerto Rico
Query!
State/province [94]
0
0
Arecibo
Query!
Country [95]
0
0
Singapore
Query!
State/province [95]
0
0
Singapore
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
LA Coruña
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Madrid
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Vizcaya
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Barcelona
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Burgos
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Malaga
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Murcia
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Valladolid
Query!
Country [104]
0
0
Switzerland
Query!
State/province [104]
0
0
Aarau
Query!
Country [105]
0
0
Switzerland
Query!
State/province [105]
0
0
Bern
Query!
Country [106]
0
0
Switzerland
Query!
State/province [106]
0
0
Binningen
Query!
Country [107]
0
0
Switzerland
Query!
State/province [107]
0
0
Lausanne
Query!
Country [108]
0
0
Switzerland
Query!
State/province [108]
0
0
Lugano
Query!
Country [109]
0
0
Switzerland
Query!
State/province [109]
0
0
Luzern
Query!
Country [110]
0
0
Switzerland
Query!
State/province [110]
0
0
Zürich
Query!
Country [111]
0
0
United Arab Emirates
Query!
State/province [111]
0
0
Abu dhabi
Query!
Country [112]
0
0
United Arab Emirates
Query!
State/province [112]
0
0
Dubai
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Bedford
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
Belfast
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
Birmingham
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Bradford
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Bristol
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Cardiff
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Cheltenham
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Colchester
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Coventry
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Frimley
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Harrow
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Hull
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Leeds
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Liverpool
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
London
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Maidstone, Kent
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Manchester
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Newcastle upon Tyne
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
Norfolk
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Oxford
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Sheffield
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Southampton
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Sunderland
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Torquay
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The VOYAGER study is a primary data collection, non-interventional, prospective,
multinational, multicenter study. It is designed to collect real-world, long-term data to
explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors
driving the treatment decisions among patients being treated with specified Roche
ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved
retinal indications (neovascular age-related macular degeneration [nAMD] and diabetic macular
edema [DME]) in routine clinical practice. This study will not provide or make
recommendations on use of any products including Roche products; treatment decisions will be
determined by the treating physician and must be made independently to the decision to
participate in this study. Participation in this study will not change or influence a
patient's standard of care in any way.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05476926
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Reference Study ID Number: MR41927 https://forpatients.roche.com/
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-662-6728 (U.S. Only)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05476926
Download to PDF